Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
ASCO
Filter by Topic
ASCO 2014 Highlights
ASCO 2014 – Colorectal and Head & Neck Cancer
ASCO 2014 – Immuno-Oncology
ASCO 2014 – Lung Cancer
ASCO 2015 - Lung Cancer
ASCO 2015 Highlights
ASCO 2016 – Lung Cancer
ASCO 2017 – Multiple Myeloma
ASCO 2018 Insights
ASCO 2019
ASCO 2020 Cholangiocarcinoma
ASCO Breast Cancer Symposium
ASCO Quality Care Symposium
ASCO’s 1st Quality Care Symposium
RTOG 0522: The KRAS Variant and Response to Cetuximab
ASCO 2014 – Colorectal and Head & Neck Cancer
,
ASCO
Conference Correspondent
In many cancers,
KRAS
mutations can predict cancer risk, unique cancer biology, and response to certain therapeutic agents. RTOG 0522 was a phase 3 trial of cisplatin/radiation ± cetuximab for patients with locally advanced SCCHN, evaluating whether
KRAS
mutation status would predict the response to cetuximab in these patients (Weidhaas JB, et al. ASCO 2014. Abstract 6000).
Read Article
Adjuvant Lapatinib Plus Chemoradiation in High-Risk Patients with SCCHN
ASCO 2014 – Colorectal and Head & Neck Cancer
,
ASCO
Conference Correspondent
Read Article
Maintenance Strategies in mCRC After First-Line Therapy
ASCO 2014 – Colorectal and Head & Neck Cancer
,
ASCO
Conference Correspondent
Read Article
Final Results of the CAIRO3 Study
ASCO 2014 – Colorectal and Head & Neck Cancer
,
ASCO
Conference Correspondent
Read Article
Prognostic Impact of Deficient Mismatch Repair in CRC
ASCO 2014 – Colorectal and Head & Neck Cancer
,
ASCO
Conference Correspondent
Read Article
Preoperative Chemoradiotherapy and Postoperative Chemotherapy in Locally Advanced Rectal Cancer—Results of the CAO/ARO/AIO-04 Trial
ASCO 2014 – Colorectal and Head & Neck Cancer
,
ASCO
Conference Correspondent
Read Article
RAS Mutation Status and FOLFOX +/- Cetuximab—The OPUS Study
ASCO 2014 – Colorectal and Head & Neck Cancer
,
ASCO
Conference Correspondent
Read Article
Pidilizumab in Relapsed Metastatic Melanoma
ASCO 2014 – Immuno-Oncology
,
ASCO
Conference Correspondent
Read Article
Nivolumab and Erlotinib in EGFR-Mutation Positive Treatment-Resistant Advanced NSCLC
ASCO 2014 – Immuno-Oncology
,
ASCO
Conference Correspondent
Read Article
Nivolumab in Chemotherapy-Naïve Advanced NSCLC
ASCO 2014 – Immuno-Oncology
,
ASCO
Conference Correspondent
Read Article
Page 10 of 19
5
6
7
8
9
10
11
12
13
14
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma